Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2020

View Archived Issues

Capsid-like particles displaying an HA trimer: a promising universal flu vaccine candidate

New partner in crime for AHR

Multiple sclerosis' early days

New ADCs including tandem-cleavage linkers show improved stability and toxicity

Epigenetic problems contribute to Parkinson's disease

Roche reports the discovery of novel CYP11B2 inhibitors

Tocilizumab may prevent risk of invasive mechanical ventilation or death in severe COVID-19

Bayer, The Broad Institute describe new PDE3A and/or PDE3B inhibitors

FDA clears IND application for phase Ib study of NT-I7 plus Kymriah in r/r LBCL

Positive topline data presented from phase III CONTESSA study of tesetaxel

Orexin receptor type 1 antagonists discovered at Heptares Therapeutics

Hubei Bio-Pharmaceutical, Humanwell Healthcare patent E-NPP 2 inhibitors

Bristol-Myers Squibb discovers TYK2 inhibitors

New adenosine A2A/A2B receptor antagonists identified at Incyte

Pivotal phase III INSPIRE study of rigosertib in MDS does not meet primary endpoint

Keytruda receives two new approvals in Japan

Imugene begins phase I study of IMU-201 in NSCLC

Early clinical reports suggest utility of Aggrastat for COVID-19-related thrombotic complications

AstraZeneca begins first-in-human study of AZD-7442 for prevention and treatment of COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...